Layer 1

IC-MEDTECH AND LIQUID CRYSTAL PHARMACEUTICALS™

IC-MedTech is a San Diego biotech engaged in drug development for the treatment of cancer and other diseases. The company's products currently include pre-clinical and clinical compounds for solid tumors, blood borne cancers and sexually transmitted diseases. The most promising of these new drugs are Apatone® and Tolecine™.

The company specializes in identification and application of biologically active liquid crystals. Liquid crystals are essential for life and occur naturally in all organisms. Examples include DNA, protein and cellular membranes. IC-MedTech's products are nano-scale small molecules referred to as LCP's (Liquid Crystal Pharmaceuticals™). These compounds often rely on the unique properties of liquid crystals.

Learn More »

MESSAGE FROM TOM MILLER, CEO

If you, your family, or friends have been touched by cancer, you already know:

We must find a better way.

Learn More »

LATEST NEWS

A 12 Week, Open Label, Phase I/IIa Study Using Apatone® for the Treatment of Prostate Cancer Patients Who Have Failed Standard Therapy.
Link to the Study »

FDA approves Apatone® orphan drug designation

July 31, 2007 - The FDA has granted Apatone orphan drug status for treatment of inoperable bladder cancer stage III and IV. Only the fourth drug ever to receive this designation from the FDA.
Learn More »

Kent State University, Summa Heath System and IC-MedTech announce development of Liquid Crystal Pharmaceuticals™

This ground-breaking technology utilizes the properties of lyotropic liquid crystals, or organic liquid crystals. Essential for life, examples of naturally occurring lyotropic liquid crystals include DNA and cholesterol. All biological membranes exhibit liquid crystalline behavior.
Learn More »

Lead compound successfully completes Phase I/IIa clinical trial in prostate cancer

Apatone has since completed clinical study for safety and as an oral monotherapy in late-stage prostate cancer. Investigators Dr. A. Diokno, Chief Medical Officer for William Beaumont Hospital (Michigan) and Dr. J. Summers, Director for Urologic research at Summa Hospital (Ohio), reported: "There is evidence of therapeutic benefit based on PSA kinetics. The more advanced the disease, the more pronounced the effect seemed to be."

© 2007 IC-MedTech